Mukul Minocha1, Jiewei Zeng2, Jeroen K Medema3, Ahmed A Othman4. 1. Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, 60064, USA. 2. Discovery and Early Pipeline Statistics, AbbVie, North Chicago, IL, 60064, USA. 3. Immunology Development, AbbVie, North Chicago, IL, 60064, USA. 4. Clinical Pharmacology and Pharmacometrics, AbbVie, North Chicago, IL, 60064, USA. ahmed.othman@abbvie.com.
Abstract
BACKGROUND AND OBJECTIVE:Venetoclax is an oral selective Bcl-2 inhibitor approved for the treatment of patients with chronic lymphocytic leukemia with 17p deletion. Mechanistic and preclinical evidence warranted evaluation of venetoclax for the treatment of systemic lupus erythematosus (SLE). This work characterized the pharmacokinetics of venetoclax in female subjects with SLE. METHODS: Single (10-500 mg) and multiple (30-600 mg) escalating doses of venetoclax or matching placebo were evaluated using randomized, double-blind, placebo-controlled designs (6 active and 2 placebo per dose with 73 unique SLE patients enrolled, 25 of whom enrolled twice). The multiple-dose evaluation consisted of two cycles, each with once-daily dosing for 7 days followed by a 21-day washout. Non-compartmental and population pharmacokinetic analyses of venetoclax serial plasma concentrations were conducted. RESULTS:Venetoclax exhibited approximately dose-proportional exposures, with peak concentrations observed 4-8 h post-dose. Venetoclax steady-state exposures were achieved by day 4 of dosing, and the median area under the plasma concentration-time curve (AUC) accumulation ratio ranged from 1.1 to 1.5. A two-compartment model with first-order absorption and elimination described venetoclax pharmacokinetics. The estimates (95% bootstrap confidence interval) for venetoclax apparent clearance, central and peripheral volumes of distribution, intercompartmental clearance, absorption rate constant, and lag time were 16.3 L/h (14.6-17.9), 37 L (26-57), 122 L (98-183), 3.7 L/h (2.6-5.0), 0.13 h-1 (0.11-0.17), and 1.6 h (1.6-1.7), respectively. The population estimate for venetoclax terminal-phase elimination half-life was approximately 28 h. CONCLUSIONS: In female subjects with SLE, venetoclax displayed pharmacokinetic characteristics consistent with previous observations in subjects with hematologic malignancies. CLINICALTRIALS. GOV IDENTIFIER: NCT01686555.
RCT Entities:
BACKGROUND AND OBJECTIVE:Venetoclax is an oral selective Bcl-2 inhibitor approved for the treatment of patients with chronic lymphocytic leukemia with 17p deletion. Mechanistic and preclinical evidence warranted evaluation of venetoclax for the treatment of systemic lupus erythematosus (SLE). This work characterized the pharmacokinetics of venetoclax in female subjects with SLE. METHODS: Single (10-500 mg) and multiple (30-600 mg) escalating doses of venetoclax or matching placebo were evaluated using randomized, double-blind, placebo-controlled designs (6 active and 2 placebo per dose with 73 unique SLEpatients enrolled, 25 of whom enrolled twice). The multiple-dose evaluation consisted of two cycles, each with once-daily dosing for 7 days followed by a 21-day washout. Non-compartmental and population pharmacokinetic analyses of venetoclax serial plasma concentrations were conducted. RESULTS:Venetoclax exhibited approximately dose-proportional exposures, with peak concentrations observed 4-8 h post-dose. Venetoclax steady-state exposures were achieved by day 4 of dosing, and the median area under the plasma concentration-time curve (AUC) accumulation ratio ranged from 1.1 to 1.5. A two-compartment model with first-order absorption and elimination described venetoclax pharmacokinetics. The estimates (95% bootstrap confidence interval) for venetoclax apparent clearance, central and peripheral volumes of distribution, intercompartmental clearance, absorption rate constant, and lag time were 16.3 L/h (14.6-17.9), 37 L (26-57), 122 L (98-183), 3.7 L/h (2.6-5.0), 0.13 h-1 (0.11-0.17), and 1.6 h (1.6-1.7), respectively. The population estimate for venetoclax terminal-phase elimination half-life was approximately 28 h. CONCLUSIONS: In female subjects with SLE, venetoclax displayed pharmacokinetic characteristics consistent with previous observations in subjects with hematologic malignancies. CLINICALTRIALS. GOV IDENTIFIER: NCT01686555.
Authors: C Miret; J Font; R Molina; M Garcia-Carrasco; X Filella; M Ramos; R Cervera; A Ballesta; M Ingelmo Journal: Anticancer Res Date: 1999 Jul-Aug Impact factor: 2.480
Authors: P Lu; R Fleischmann; C Curtis; S Ignatenko; S H Clarke; M Desai; S L Wong; K M Grebe; K Black; J Zeng; J Stolzenbach; J K Medema Journal: Lupus Date: 2017-07-10 Impact factor: 2.911
Authors: Andrew J Souers; Joel D Leverson; Erwin R Boghaert; Scott L Ackler; Nathaniel D Catron; Jun Chen; Brian D Dayton; Hong Ding; Sari H Enschede; Wayne J Fairbrother; David C S Huang; Sarah G Hymowitz; Sha Jin; Seong Lin Khaw; Peter J Kovar; Lloyd T Lam; Jackie Lee; Heather L Maecker; Kennan C Marsh; Kylie D Mason; Michael J Mitten; Paul M Nimmer; Anatol Oleksijew; Chang H Park; Cheol-Min Park; Darren C Phillips; Andrew W Roberts; Deepak Sampath; John F Seymour; Morey L Smith; Gerard M Sullivan; Stephen K Tahir; Chris Tse; Michael D Wendt; Yu Xiao; John C Xue; Haichao Zhang; Rod A Humerickhouse; Saul H Rosenberg; Steven W Elmore Journal: Nat Med Date: 2013-01-06 Impact factor: 53.440
Authors: Suresh K Agarwal; Courtney D DiNardo; Jalaja Potluri; Martin Dunbar; Hagop M Kantarjian; Rod A Humerickhouse; Shekman L Wong; Rajeev M Menon; Marina Y Konopleva; Ahmed Hamed Salem Journal: Clin Ther Date: 2017-02-01 Impact factor: 3.393
Authors: Ahmed Hamed Salem; Beibei Hu; Kevin J Freise; Suresh K Agarwal; Dilraj S Sidhu; Shekman L Wong Journal: Clin Drug Investig Date: 2017-03 Impact factor: 2.859
Authors: A Strasser; S Whittingham; D L Vaux; M L Bath; J M Adams; S Cory; A W Harris Journal: Proc Natl Acad Sci U S A Date: 1991-10-01 Impact factor: 11.205